PK & Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers

Summary

A randomized, double-blind, placebo controlled, two period crossover study to investigate the pharmacokinetics, tolerability and cognitive effects of 8 days dosing of CNV1014802 in healthy young versus elderly male and female subjects. Treatment periods will be separated by 13 days. The primary outcome measures are pharmacokinetics (PK) and tolerability.

Timeline

Start

2015-02-03

Primary completion

2015-04-20

Completion

2015-04-20

Drugs

Indications